Belimumab (Benlysta) listed in ON

April 29, 2024 – Lupus Canada is pleased to share that Benlysta (indication Lupus Nephritis) is listed in Ontario effective April 17, 2024.


We are pleased to provide you with the Summary of Changes – April 2024 to Edition No. 43 of the Ontario Drug Benefit (ODB) Formulary / Comparative Drug Index (Formulary), which becomes effective April 30, 2024. The Edition No. 43 document will be posted on the Ministry’s website by April 30, 2024.

The Ministry has posted a new file with the listing changes for download and review (Edition No. 43, Summary of Changes – April 2024). It is accessible from the Ministry’s website:

In addition, the Formulary, Summaries of Changes and Bulletins, including a searchable electronic version of the Formulary (e-Formulary), are also accessible from the Ministry’s website: – The e-Formulary will be updated on the effective date – April 30, 2024. 

Exceptional Access Program (EAP) Products

Benlysta (belimumab) 120mg/5mL, 400mg/20mL Inj Sol (GSK) – Effective Date: April 17, 2024

For the treatment of patients with active lupus nephritis (LN), based on criteria.

Lupus Blog Articles:

Lupus Canada Recipe Corner | Strawberry Rhubarb Crisp


Living with Lupus Corner with Mauricia Ambrose